New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
07:02 EDTMYGNPiper sees negative BRACA decisions as isolated for Myriad Genetics
Piper Jaffray says its work suggests "little negative provider updates" for Myriad Genetics (MYGN) beyond Horizon BCBS recently naming LabCorp (LH) as its in-patient BRCA test provider and Health Plus's update urging the discontinuation of Myriad for BRCA testing. The firm believes recent negative BRACAnalysis decisions are isolated and keeps an Overweight rating on Myriad with a $44 price target.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use